Skinbiotherapeutics Share Discussion Threads

[slartybartfaster] 24/11/2017 15:28

Much better said ricky.

[slartybartfaster] 24/11/2017 15:26

How is sbtx safer investment than opti? Sbtx has a very portfolio of potential products, Opti have a much broader range products across a range of health and wellbeing sectors and has product on shelves now not 12 months away. Most of us a realists not dreaming rampers. Tick tock, i expect sbtx free shares in about 5 to 6 months.

[riskybusiness1] 24/11/2017 15:21

He's invested in s single area of microbiome yet unproven...Opti investors are invested in 4 separate areas with a 5th (Psychobiotics) likely to become the next. Opti have derisked it's products, has multiple partners and routes to market and is gaining commercial traction. Skin should do well but to say it's less risky than Opti is an extremely uneducated view. True your investment here may grow 10x current levels but if it does so will Optis £5m holding which will be distributed back to shareholders. From SOHs standing he will gain 8% of Skin once this distribution has been completed. Give it a rest now bob and look at the motives behind those who brought Skin to market and it may click in there at some point.

[loungeact] 24/11/2017 14:44

Shazbo - He sold his OPTI shares and is heavily invested in SBTX, so now he posts the same stuff repeatedly in an attempt to ramp. He also wants to mislead investors and put them off OPTI.

[bobalot] 24/11/2017 14:34

Another fanatic just arrived from OPTI....SBTX IS A FAR BETTER AND SAFER INVESTMENT for PI's imo


DREAM ON ABOUT FREE SHARES FROM OPTI ON A 1:1 RATIO.....fantasy, pie in the sky.

[loungeact] 24/11/2017 14:34

I wonder if Bobalot understood all that, wait...let me translate...“WHAT IT MEANS FOR SHAREHOLDERS, TYPICALLY THEY RETAIN THEIR POSITION IN OPTIBIOTIX, BUT THEY ALSO GAIN A PROPORTIONAL POSITION IN THE NEW LISTED COMPANY. SO FOR A SHAREHOLDER POINT OF VIEW, IT’S A WAY OF GREATLY INCREASING THEIR SHAREHOLDING.” STEPHEN O’HARA - CEO OF OPTIBIOTIX.

[slartybartfaster] 24/11/2017 14:32

Unfortunately bob dont understand certain aspects of the markets, me included. I wouldnt accuse someone trying to help be of being a 'unreliable and a con artist' instead of being grateful for the help.

[riskybusiness1] 24/11/2017 14:14

SOH was the mastermind behind the Skinbio acquisition and IPO listing he will do what's best for Opti shareholders being the largest shareholder with a 20% holding including shares held under option.Bob trying to antagonise Opti holders is ridiculously stupid considering how SKINBIO came in to existence.

[loungeact] 24/11/2017 13:48

This a great video from last year, where SOH talks about listing Skinbiotheraputics - -- “What it means for shareholders, typically they retain their position in Optibiotix, but they also gain a proportional position in the new listed company. So for a shareholder point of view, it’s a way of greatly increasing their shareholding.” Stephen O’Hara - CEO of Optibiotix. -- It's a shame for anyone that sold their OPTI shares. LOLOLOL

[bobalot] 24/11/2017 13:23

SkinBiotherapeutics readying for cosmetic cream launch after safety test success

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours

First product will be skin care cream

SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.

Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.
Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”
SkinBiotix might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category.

“SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.”

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.
Shares rose 1% to 10.3p.

[bobalot] 24/11/2017 13:11

Here is a recap of some recent SBTX news.

SkinBiotherapeutics readying for cosmetic cream launch after safety test success


SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours

First product will be skin care cream

SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.
Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.

Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”
SkinBiotix might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category.

“SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.”

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.
Shares rose 1% to 10.3p.

[bobalot] 24/11/2017 13:09

It is pleasing to see the OPTI FANATICS are busy on the other thread today...they are still hoping for a 30% rise --- blinded by hype and fake intel....lol

[slartybartfaster] 23/11/2017 19:18

The overwhelming votes clearly show bobalot-losttheplot has lost the board, the lurkers have come out to vote and it is a land slide. Im left wondering how many have the idiot filtered now. The liars campaign has backfired on you bobalot-losttheplot.

[bobalot] 23/11/2017 18:46

People like you will never learn --- blinded by hype...lol

[bobalot] 23/11/2017 18:28

Except they don't own the business anymore as a wholly owned subsidiary --- they cashed out in a debt for equity swap and now only own 41% of the company -- at least 50-52% IS NEEDED to have a controlling interest. Despite what some posters are touting.

[pglancy] 23/11/2017 17:30

Optibiotix should be listed in the Bionow investment deal of the year awards for turning 560k into 12m in 12 months and still have 5m on the books waiting to pay out as a special divi. Just a thought.

[bobalot] 23/11/2017 16:26

SkinBioTherapeutics Retweeted Bionow

SkinBioTherapeutics shortlisted for the Bionow investment deal of the year awards.

SkinBioTherapeutics added,


Bionow‏ @Bionow
Follow @Bionow

More
Bionow awards shortlists announced! Bionow Investment Deal of the Year Award (Sponsored by @QIAGENscience) shortlist @ADCBIO @Acceleris @Microbiosensor @SkinBioT Sky Medical Technology #bionowawards17 hxxp://ow.ly/QKfx30gJcQw


SKINBIO MIGHT WIN AN AWARD SOON

[bobalot] 23/11/2017 15:56

you people really take the biscuit, SBTX is not a subsidiary....more looney tunes.

[pglancy] 23/11/2017 15:49

Try counting the votes. The email confirms what everyone agrees with, only you cant see it.